The area of medicine and healthcare services known as "women's health" is committed towards the particular biological, physiological, and psychological requirements and problems that affect women at all stages of life. It covers a range of topics related to women-specific wellness promotion, gynecological care, reproductive health, and sexual health. In addition, gender-specific health issues related to menstruation, contraception, pregnancy, childbirth, menopause, and diseases such as osteoporosis, endometriosis, breast cancer, and ovarian cancer are covered under women's health. Women's health also places a strong emphasis on screenings, preventative care, and interventions meant to close the gender gaps in healthcare outcomes, access, and quality.
Access Full Report @ https://www.databridgemarketresearch.com/reports/north-america-and-europe-womens-health-market
North America and Europe Women’s Health Market is expected to reach USD 16.49 billion by 2031, from USD 9.12 billion in 2023, growing at the CAGR of 8.0% in the forecast period of 2024 to 2031.
Key Findings of the Study
Changing Lifestyle and Environmental Factors Impacting Health
Rapid urbanization, sedentary lives, unhealthy eating patterns, and exposure to environmental pollutants are all factors in the rising rates of long-term medical conditions and problems with women's reproductive health. Women are increasingly experiencing obesity, cardiovascular disease, and type 2 diabetes as a result of sedentary lifestyles and poor dietary choices. This has increased demand for preventive healthcare services, weight-management plans, and metabolic health therapies. Women are increasingly seeking mentally and physically interventions, individualized dietary regimens, and integrative and complementary therapies to enhance their overall well-being, as a result of shifting societal standards and growing awareness of the significance of holistic health and wellbeing. Healthcare practitioners, pharmaceutical firms, and wellness brands are adapting and broadening their product lines in response to these changing trends in order to satisfy the increasing need for comprehensive, individualized, and ecologically friendly healthcare solutions for women. Thus, the changing lifestyle and environmental factors impacting health is a major driver for the market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Treatment (Drugs and Device), Indication (Cancer, Reproductive Health, Urological Disorders, Hypothyroidism, Post-Menopausal Syndrome, and Others), Delivery Mode (Prescription and Over the Counter), Drug Type (Branded and Generic), Care Type (General Healthcare & Wellness, Pregnancy & Nursing Care, Pelvic & Uterine Healthcare, and Others), End User (Hospitals and Clinics, Gynecology Centers, Homecare Settings, Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, Online Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, U.K., and Rest of Europe
|
|
Market Players Covered
|
Lilly (U.S.), Abbott (U.S.), Lupin (India), GSK plc. (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Vertical Pharmaceuticals, LLC (U.S.), Veru Inc. (U.S.), and Pfizer Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
North America and Europe women’s health market is categorized into seven notable segments which are based on treatment, indication, delivery mode, drug type, care type, end user, and distribution channel.
- On the basis of treatment, the North America and Europe women’s health market is segmented into drugs and devices
In 2024, the drugs segment is expected to dominate the North America and Europe women’s health market
In 2024, the drugs segment is expected to dominate the market with the market share of 56.53% in North America and 58.44% in Europe as they are widely used and first line of treatment.
- On the basis of indication, the North America and Europe women’s health market is segmented into cancer, reproductive health, urological disorders, hypothyroidism, post-menopausal syndrome, and others
In 2024, the cancer segment is expected to dominate the North America and Europe women’s health market
In 2024, the cancer segment is expected to dominate the market with the market share of 38.77% in North America and 40.16% in Europe due to the higher prevalence of cancer among the female population.
- On the basis of delivery mode, the North America and Europe women’s health market is segmented into prescription and over the counter. In 2024, the prescription segment is expected to dominate the market with the market share of 62.71% in North America and 63.06% in Europe
- On the basis of drug type, the North America and Europe women’s health market is segmented into branded and generic. In 2024, the branded segment is expected to dominate the market with the market share of 58.80% in North America and 59.90% in Europe
- On the basis of care type, the North America and Europe women’s health market is segmented into general healthcare & wellness, pregnancy & nursing care, pelvic & uterine healthcare, and others. In 2024, the general healthcare & wellness segment is expected to dominate the market with the market share of 43.62% in North America and 45.11% in Europe
- On the basis of end user, the North America and Europe women’s health market is segmented into hospitals and clinics, gynecology centers, homecare settings, homecare setting, research institutes, and others. In 2024, the hospitals and clinics segment is expected to dominate the market with the market share of 35.15% in North America and 37.67% in Europe
- On the basis of distribution channel, the North America and Europe women’s health market is segmented into direct tenders, retail sales, online sales, and others. In 2024, the direct tenders segment is expected to dominate the market with the market share of 46.67% in North America and 48.48% in Europe
Major Players
Data Bridge Market Research analyzes Pfizer Inc. (U.S.), Lilly (U.S.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), and GSK plc. (U.K.) as the major players operating in the North America women’s health market.
Data Bridge Market Research analyzes Pfizer Inc. (U.S.), Lilly (U.S.), Novartis AG (Switzerland), GSK plc. (U.K.), and Abbott (U.S.) as the major players operating in the Europe women’s health market.
Market Development
- In November 2023, Lupin entered into an exclusive partnership with Amman Pharmaceuticals Industries (Amman Pharma), a prominent pharmaceutical manufacturer with a presence in the MENA region and various global markets. This collaboration involves the marketing and commercialization rights for Ranibizumab, a biosimilar of Lucentis. This strategic partnership allows Lupin to tap into new regions and expand its market presence, ultimately enhancing the company's position in the pharmaceutical industry
- In July 2023, GSK plc. announced that the U.S. Food and Drug Administration (FDA) approved Jemperli (dostarlimab) as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test. This helped the company to expand its product offering
- In August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a once-daily, single-pill therapy for the management of moderate to severe pain associated with endometriosis in premenopausal women. The treatment course may last up to 24 months. This helped the company to expand its product range
- In November 2020, Avion Pharmaceuticals (subsidiary of Alora Pharmaceuticals, LLC), LLC, a specialty pharmaceutical firm, has secured an exclusive license and commercialization agreement with Aspen Pharma USA Inc. and Aspen Global Incorporated. This agreement grants Avion exclusive rights to relaunch Cenestin (synthetic conjugated estrogens, A) tablet, the sole plant-derived blend of nine conjugated estrogens
- In June 2020, AbbVie Inc. in collaboration with Neurocrine Biosciences, Inc., has announced that the U.S. Food and Drug Administration (FDA) has granted approval for ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), allowing for a treatment duration of up to 24 months. ORIAHNN marks the inaugural FDA-approved non-surgical, oral treatment option for addressing heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. This approval expandsthe company’s portfolio of women's health medications and establishes Neurocrine Biosciences as a key player in the field
Regional Analysis
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, U.K., and rest of Europe.
As per Data Bridge Market Research Analysis:
North America is the dominant and fastest growing region in the North America and Europe women’s health market
North America is expected to be the dominant and fastest growing region in the market due to the presence of advanced healthcare infrastructure and technological innovation for women’s healthcare sector.
For more detailed information about the North America and Europe women’s health market report, click here – https://www.databridgemarketresearch.com/reports/north-america-and-europe-womens-health-market
